Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2006

View Archived Issues

Axcan updates clinical progress

COX-2 NSAIDs target tNOX tumor-selectively in their anticancer activity / News in Context

Radiotracers allow for assessment of neuropathology in AD

Enrollment completed in phase II/III study of MN-305 for GAD

Boehringer Ingelheim closes treatment arm in Aptivus study

Procyon shareholders approve Cellpep acquisition

MorphoSys updates development strategy

Second phase III trial under way for alfimeprase in catheter occlusion

CHF-1512 superior to standard levodopa/carbidopa in Parkinson's disease patients

Phase I and II studies assess velafermin in oral mucositis

Rotigotine receptor profile, effects in Parkinson's disease model reported

Combined RESIST-1 and RESIST-2 data reveal efficacy of tipranavir plus ritonavir

Mobilization of hematopoietic stem cells increased with AMD-3100

SM-360320: targeting TLR7 for HCV therapy

New phase I/II study evaluates MyVax personalized immunotherapy for CLL

AMDL's DR-70 cancer test kit shows efficacy as tumor marker for ovarian cancer

New phase I study for NGX-267 for Alzheimer's disease

PC-DAC:Exendin-4 cleared for phase I/II study in type 2 diabetes

Transition Therapeutics to acquire outstanding shares of Ellipsis Neurotherapeutics

Chiron updates status of H5N1 avian influenza vaccine contracts

DPP-IV inhibitor GRC-8200 well tolerated in phase I study

TP-10 shows no significant efficacy in female cardiac bypass surgery patients

New therapeutics for cancer disclosed in recent patent literature

FDA approval for Zegerid Capsules

Emsam approved for major depressive disorder

U.S. approval for Rituxan in active rheumatoid arthritis

Compounds with potential applicability in neurological disorders patented

Novel antiplatelet agents claimed in recent Daiichi patent

New data on rPA anthrax vaccine presented

Lassa fever vaccine may protect against all strains of Lassa virus